⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420322 | 0.82 | DRD2 (0.31) | — | |
| SCHEMBL26650897 | 0.81 | CHRNB2 (0.37) | — | |
| SCHEMBL29659652 | 0.81 | EGFR (0.33) | — | |
| SCHEMBL20230799 | 0.78 | — | — | |
| SCHEMBL29265688 | 0.77 | L3MBTL1 (0.42) | — | |
| SCHEMBL16653865 | 0.77 | L3MBTL1 (0.42) | — | |
| SCHEMBL19439698 | 0.77 | PAOX (0.38) | — | |
| SCHEMBL16653961 | 0.77 | PAOX (0.38) | — | |
| SCHEMBL20235764 | 0.76 | LMNA (0.33) | — | |
| SCHEMBL13245020 | 0.76 | L3MBTL1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | claimed |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-18 | — | — | US | claimed |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | disclosed |